Finding Solutions to Thrive After Birth Asphyxia in Africa
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Neonatal encephalopathy (NE) is the third leading cause of under 5-year mortality and
contributes substantially to long-term neurological morbidity worldwide. In low-income
countries (LICs), families often lack the resources to care for affected children. For those
with disabilities, stigma is high, and social and emotional impacts are substantial.
Improving our understanding of NE in LICs is crucial if intervention strategies are
developed. Providing access to an affordable and easy-to-administer treatment after birth may
improve survival, early brain development and later outcome, maximizing developmental
potential.
The primary objective of this study is to investigate the feasibility, safety and
tolerability of administering sildenafil as a neuroprotective/neurorestorative strategy to
improve early brain development in a cohort of children with NE in Uganda.
Phase:
Phase 1
Details
Lead Sponsor:
Pia Wintermark
Collaborators:
Kawempe National Referral Hospital Saint Francis Memorial Hospital Walimu